These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 28225516)

  • 41. Macrophage activation syndrome in a patient with axial spondyloarthritis on adalimumab.
    Baker R; Liew JW; Simonson PD; Soma LA; Starkebaum G
    Clin Rheumatol; 2019 Feb; 38(2):603-608. PubMed ID: 30535729
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Experience with hemophagocytic lymphohistiocytosis/macrophage activation syndrome at a single institution.
    Gupta AA; Tyrrell P; Valani R; Benseler S; Abdelhaleem M; Weitzman S
    J Pediatr Hematol Oncol; 2009 Feb; 31(2):81-4. PubMed ID: 19194188
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Histiocytic disorders: recent insights into pathophysiology and practical guidelines.
    Filipovich A; McClain K; Grom A
    Biol Blood Marrow Transplant; 2010 Jan; 16(1 Suppl):S82-9. PubMed ID: 19932759
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Macrophage activation syndrome with lung involvement complicating adult-onset Still's disease.
    Wang CR; Tsai YS; Ma IC
    Neth J Med; 2018 Dec; 76(10):442-444. PubMed ID: 30569890
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Successful therapy of macrophage activation syndrome with dexamethasone palmitate.
    Nakagishi Y; Shimizu M; Kasai K; Miyoshi M; Yachie A
    Mod Rheumatol; 2016 Jul; 26(4):617-20. PubMed ID: 24754272
    [TBL] [Abstract][Full Text] [Related]  

  • 46. An unusual presentation of purine nucleoside phosphorylase deficiency mimicking systemic juvenile idiopathic arthritis complicated by macrophage activation syndrome.
    Arduini A; Marasco E; Marucci G; Pardeo M; Insalaco A; Caiello I; Moneta GM; Prencipe G; De Benedetti F; Bracaglia C
    Pediatr Rheumatol Online J; 2019 May; 17(1):25. PubMed ID: 31118063
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Novel use of rituximab in macrophage activation syndrome secondary to systemic lupus erythematosus.
    Junga Z; Stitt R; Tracy C; Keith M
    BMJ Case Rep; 2017 Aug; 2017():. PubMed ID: 28827301
    [TBL] [Abstract][Full Text] [Related]  

  • 48. High-Volume Hemofiltration in Critically Ill Patients With Secondary Hemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome: A Prospective Study in the PICU.
    Cui Y; Zhang YC; Kang YL; Ren YQ; Miao HJ; Wang F
    Pediatr Crit Care Med; 2016 Oct; 17(10):e437-e443. PubMed ID: 27487914
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Not all hemophagocytes are created equally: appreciating the heterogeneity of the hemophagocytic syndromes.
    Canna SW; Behrens EM
    Curr Opin Rheumatol; 2012 Jan; 24(1):113-8. PubMed ID: 22089101
    [TBL] [Abstract][Full Text] [Related]  

  • 50. An international consensus survey of diagnostic criteria for macrophage activation syndrome in systemic juvenile idiopathic arthritis.
    Davì S; Consolaro A; Guseinova D; Pistorio A; Ruperto N; Martini A; Cron RQ; Ravelli A;
    J Rheumatol; 2011 Apr; 38(4):764-8. PubMed ID: 21285158
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Macrophage activation syndrome triggered by coeliac disease: a unique case report.
    Palman J; May J; Pilkington C
    Pediatr Rheumatol Online J; 2016 Dec; 14(1):66. PubMed ID: 27938384
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Positive immuno-reactions in a case of unilateral scleroderma or progressive hemiatrophy.
    Oka M; Ruotsi A
    Acta Rheumatol Scand; 1969; 15(1):29-34. PubMed ID: 5360634
    [No Abstract]   [Full Text] [Related]  

  • 53. Cytokines in systemic juvenile idiopathic arthritis and haemophagocytic lymphohistiocytosis: tipping the balance between interleukin-18 and interferon-γ.
    Put K; Avau A; Brisse E; Mitera T; Put S; Proost P; Bader-Meunier B; Westhovens R; Van den Eynde BJ; Orabona C; Fallarino F; De Somer L; Tousseyn T; Quartier P; Wouters C; Matthys P
    Rheumatology (Oxford); 2015 Aug; 54(8):1507-17. PubMed ID: 25767156
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pronounced hyperferritinemia: expanding the field of hemophagocytic lymphohistiocytosis.
    Henter JI
    Pediatr Blood Cancer; 2008 Jun; 50(6):1127-9. PubMed ID: 18260123
    [No Abstract]   [Full Text] [Related]  

  • 55. Primary Hemophagocytic Lymphohistiocytosis and Macrophage Activation Syndrome: The Importance of Timely Clinical Differentiation.
    Grom AA
    J Pediatr; 2017 Oct; 189():19-21.e1. PubMed ID: 28838727
    [No Abstract]   [Full Text] [Related]  

  • 56. Systemic Juvenile Idiopathic Arthritis Complicated by Macrophage Activation Syndrome.
    Wagner-Weiner L
    Pediatr Ann; 2015 Jun; 44(6):e142-7. PubMed ID: 26114369
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Determination of an appropriate cut-off value for ferritin in the diagnosis of hemophagocytic lymphohistiocytosis.
    Lehmberg K; McClain KL; Janka GE; Allen CE
    Pediatr Blood Cancer; 2014 Nov; 61(11):2101-3. PubMed ID: 24753034
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Treatment of hemophagocytic lymphohistiocytosis with alemtuzumab in systemic lupus erythematosus.
    Keith MP; Pitchford C; Bernstein WB
    J Clin Rheumatol; 2012 Apr; 18(3):134-7. PubMed ID: 22426581
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Macrophage activation syndrome in a newborn infant born to a mother with autoimmune disease.
    Park JH; Kim SH; Kim HJ; Lee SJ; Jeong DC; Kim SY
    J Perinatol; 2015 Feb; 35(2):158-60. PubMed ID: 25627282
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Recent advances in diagnostic and therapeutic guidelines for primary and secondary hemophagocytic lymphohistiocytosis.
    Ramachandran S; Zaidi F; Aggarwal A; Gera R
    Blood Cells Mol Dis; 2017 May; 64():53-57. PubMed ID: 28433836
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.